newsfilter
← Latest News
Business Wire·

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

PALIZADE Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis to initiate in first half of 2023 KZR-261 dose escalation study currently enrolling sixth cohort; the dose expansion study expected to